1. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002. 96:1004–1017.
2. Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet. 2000. 38:271–290.
3. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992. 76:334–341.
4. Wright SW, Chudnofsky CR, Dronen SC, Kothari R, Birrer P, Blanton DM, Bruner A. Comparison of midazolam and diazepam for conscious sedation in the emergency department. Ann Emerg Med. 1993. 22:201–205.
Article
5. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984. 61:27–35.
Article
6. Boswinkel JP, Litman RS. Sedating patients for radiologic studies. Pediatr Ann. 2005. 34:650–654.
Article
7. Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth. 2005. 95:377–383.
Article
8. Vaughn RL, Bennett CR. Fentanyl chest wall rigidity syndrome: a case report. Anesth Prog. 1981. 28:50–51.
9. Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996. 84:812–820.
Article
10. Hoke JF, Shlugman D, Dershwitz M, Michalowski P, Malthouse-Dufore S, Connors PM, Martel D, Rosow CE, Muir KT, Rubin N, Glass PS. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology. 1997. 87:533–541.
Article
11. Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir KT. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology. 1998. 89:562–573.
Article
12. Barr J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL, Shafer SL. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology. 2001. 95:324–333.
Article
13. Shafer SL. Advances in propofol pharmacokinetics and pharmacodynamics. J Clin Anesth. 1993. 5:6 Suppl 1. 14S–21S.
Article
14. Veselis RA, Reinsel RA, Feshchenko VA, Wronski M. The comparative amnestic effects of midazolam, propofol, thiopental, and fentanyl at equisedative concentrations. Anesthesiology. 1997. 87:749–764.
Article
15. White PF, Way WL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. Anesthesiology. 1982. 56:119–136.
16. Okamoto GU, Duperon DF, Jedrychowski JR. Clinical evaluation of the effects of ketamine sedation on pediatric dental patients. J Clin Pediatr Dent. 1992. 16:253–257.
17. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. Br J Anaesth. 2002. 88:669–675.
Article
18. Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010. 36:926–939.
Article
19. Maze M, Scarfini C, Cavaliere F. New agents for sedation in the intensive care unit. Crit Care Clin. 2001. 17:881–897.
Article